Beyond Air, Inc. (XAIR): Results of Operations and Financial Condition
Beyond Air, Inc. (XAIR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Beyond Air® Reports Fourth Quarter and Full Year 2026 Financial Results and Provides Corporate Update Revenue increased by 107% year-over-year to $7.7 million in the full fiscal year 2026; increased revenue by 66% YoY in the fiscal fourth
How this was made
The 30-second read
Why it matters
Key tradable elements are (1) new revenue guidance for the calendar year ending 12/31/26 and 12/31/27, (2) the FDA review status of a second-generation LungFit PH PMA supplement with expanded labeling (including transport by air/ground), and (3) Nasdaq compliance actions (reverse split) that can influence trading conditions.
Market read
This is a company-specific catalyst bundle: financial results plus explicit forward revenue guidance, paired with an FDA decision overhang and a reverse-split/compliance timeline.
What to watch
The reverse stock split and Nasdaq bid-price compliance path can affect liquidity/volatility; also, the article’s gross profit improvement is small in absolute dollars, so operating leverage may still be limited.
Background
Beyond Air filed an 8-K (Item 2.02) with Q4 and full-year FY2026 results (year ended March 31, 2026) and a corporate update, including a transition to a December 31 year-end.
Ticker impact
Beyond Air reports FY2026 revenue +107% to $7.7M, guides $8M for 12/31/26, and awaits FDA review of a second-gen LungFit PH PMA supplement.
Likely positive bias on guidance/traction, but with elevated volatility risk into FDA decision timelines and post-reverse-split trading dynamics.
The article provides concrete financial results, explicit revenue guidance for 2026/2027, and states the PMA supplement is under FDA review with expanded-label implications; these are actionable fundamentals, though the FDA outcome timing is not specified.
Market effects
Highlights demand/uptake momentum in inhaled nitric oxide devices and the importance of expanded labeling for market expansion.
Primarily US FDA/labeling-driven, with international distribution progress noted as contingent on local regulatory approvals.
If the expanded-label PMA supplement is approved, the company frames a multi-country addressable market expansion for LungFit PH.
Counterpoint
Revenue growth and guidance may not offset ongoing cash burn and large net losses; FDA review outcomes and timing could dominate near-term valuation.
Key entities
- companyBeyond Air, Inc.
Commercial-stage medical device/biopharmaceutical company focused on nitric oxide; reports FY2026 results, provides revenue guidance, and updates FDA review status for second-generation LungFit PH.
- regulatorU.S. FDA
Reviewing the PMA supplement for the second-generation LungFit PH system; approval would expand labeling and addressable market.
- exchangeNasdaq Stock Market LLC
Granted continued listing subject to regaining Bid Price Rule compliance by July 31, 2026 via a 1-for-20 reverse stock split.
